AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03064633
Drug: dexmedetomidine 80 µg
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: At the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both sides using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexmedetomidine group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexmedetomidine 80 µg.
Trial: NCT03064633
Drug: Bupivacaine 0.25% Injectable Solution
RxNorm normalized name: BUPivacaine 0.25% injectable solution
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 38 ml of the solution will be prepared to be used in transversus abdominis plane block
Trial: NCT00176527
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00176527
Drug: estramustine phosphate sodium
RxNorm normalized name: Estramustine Phosphate Sodium
DrugBank: Estramustine (DB01196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00176527
Drug: isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04377659
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive Tocilizumab 8 mg/kg i.v. at enrollment. Dose will be capped at 800 mg per infusion. If there is no improvement or toxicity, a second dose can be given 24 hrs to 5 days later.
Trial: NCT01240876
Drug: CEP-37247
RxNorm normalized name: CEP-9722
DrugBank: CEP-9722 (DB14882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5-, 1-, 3-, 6-, and 12-mg doses of CEP-37247 will be administered by the transforaminal epidural route.
Trial: NCT00795925
Drug: propiverine hydrochloride
RxNorm normalized name: propiverine hydrochloride
DrugBank: Propiverine (DB12278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: coated tablets containing 5 mg~consecutive dose escalation of 5 mg, 10 mg or 15 mg propiverine b.i.d.
Trial: NCT01573247
Drug: AKN-028
RxNorm normalized name: AKN-028
DrugBank: AKN-028 (DB12746)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 of the study is a sequential dose-escalation evaluation of AKN-028. Part 1 started as an accelerated intra-patient dose escalation design in one patient at a time (the N=1 portion), and has switched to standard 3 + 3 design with inter-cohort dose escalation when AUC of 12 μM\*hrs has been reached. Starting dose of AKN-028 was 60 mg twice a day.~During Part 2 of the study AKN-028 will be administered at the dose level selected in Part 1. Patients will be treated for a maximum of 3 cycles (first cycle of 14 days followed by 2 cycles of 21 days), with at least a 7-day treatment-free period between cycles. Patients with significant benefit after 3rd cycle may continue treatment at discretion of the investigator for as long as the patient continues to show significant benefit.
Trial: NCT01134315
Drug: Paricalcitol
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01134315
Drug: Calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01025154
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Induction Cycle: 20 mg/m\^2 IV over approximately 1 hour daily for 5 days (days 1-5)
Trial: NCT01025154
Drug: Idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction Cycle: 10 mg/m\^2 IV over approximately 30 minutes daily for 3 days (days 1-3), following clofarabine by 1 to 2 hours
Trial: NCT02561936
Drug: Rilpivirine Oral Tablet
RxNorm normalized name: rilpivirine Oral Tablet
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rilpivirine formulated as 25 mg oral tablet.
Trial: NCT02561936
Drug: Rilpivirine formulation G007
RxNorm normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rilpivirine G007 formulation as 10\*2.5 mg tablets.
Trial: NCT02561936
Drug: Rilpivirine formulation G009-01
RxNorm normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rilpivirine G009-01 formulation as 10\*2.5 mg tablets.
Trial: NCT01025154
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction Cycle: 1 g/m\^2 IV over approximately 2 hours daily for 5 days (days 1-5), follow clofarabine by 3 to 6 hours.
Trial: NCT02561936
Drug: Rilpivirine formulation G002
RxNorm normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rilpivirine G002 formulation as 10 g of 2.5 milligram per gram (mg/gm) granules.
Trial: NCT03841357
Drug: Abatacept Injection
RxNorm normalized name: abatacept Injection
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Supplied as a weekly injection via a pre-filled syringe
Trial: NCT03090412
Drug: HPPH
RxNorm normalized name: HPPH
DrugBank: 2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a (DB15243)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04603937
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal Injection
Trial: NCT01810432
Drug: Evacetrapib
RxNorm normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02836353
Drug: Somatostatin
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of short acting Somatostatin (100mcg) pre Oral glucose tolerance test
Trial: NCT02836353
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 week course of 400mg three times daily (TDS) pre Oral glucose tolerance test
Trial: NCT01940562
Drug: eltrombopag
RxNorm normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Children ≥= 40 kg BW:~From day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d. If primary end point not reached on day +28 then from day +29 - 200 mg/d (maximal dose).~Children 20-40 kg BW:~From day +1, start eltrombopag 50 mg/d. If primary end point not reached on day +14, then from day +15 - 75 mg/d. If primary end point not reached on day +28 then from day +29 - 100 mg/d.If primary end point not reached on day +42, then from day +43 and on - 150 mg/d (maximal dose).~Children \< 20 kg BW:~From day +1, start eltrombopag - 2 mg/kg/d. If primary end point not reached on day +14, then from day +15 - 3 mg/kg/d. If primary end point not reached on day +28 then from day +29 - 3.5 mg/kg (maximal dose).~If present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets.
Trial: NCT03115073
Drug: Clotrimazole
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of Clotrimazole
Trial: NCT01508195
Drug: Metformin IR tablets
RxNorm normalized name: metformin Oral Tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1.
Trial: NCT01508195
Drug: Canagliflozin/metformin IR FDC tablets
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2.
Trial: NCT01508195
Drug: Canagliflozin/metformin IR FDC tablets
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1.
Trial: NCT01508195
Drug: Canagliflozin tablets
RxNorm normalized name: Canagliflozin Tablets
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Type = exact number, unit = mg, number = 100, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 2.
Trial: NCT01508195
Drug: Metformin IR tablets
RxNorm normalized name: metformin Oral Tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
Trial: NCT04541888
Drug: CsA Ophthalmic Gel
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The CsA eye gel of 0.3 g: 0.15 mg
Trial: NCT04541888
Drug: Hypromellose Eye Drop
DrugBank: Hypromellose (DB11075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypromellose Eye Drops of 10ml：50mg, 3 times daily, 1-2 drop
Trial: NCT01385631
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
Trial: NCT00057954
Drug: Pentostatin
RxNorm normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day -3, -2: Pentostatin 4 mg/m²/d by continuous IV infusion (Total dose = 8 mg/m²)
Trial: NCT00057954
Drug: Cyclosporin (CSA)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A or tacrolimus will be administered according to institutional GVHD prophylaxis protocols. Therapeutic levels will be maintained and patients will be switched to oral agents when they can tolerate
Trial: NCT00057954
Drug: Mycophenolate mofetil (MMF)
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: At day 100 MMF will be introduced at a dose of 250 mg po BID and cyclosporine or tacrolimus will be tapered according to the discretion of the investigator. The dosage will be escalated to a maximum of 2 g/d at the discretion of the attending physician and will be tapered and discontinued at 12 months if there is no active cGVHD. Doses should be given on an empty stomach
Trial: NCT00315146
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02334631
Drug: High Volume Simethicone
RxNorm normalized name: Simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High volume simethicone is defined as 1125 mg simethicone in 750 ml of water (1.5 mg/ml).
Trial: NCT02334631
Drug: Standard Volume Simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard volume simethicone is defined as 300 mg simethicone in 200 ml of water (1.5 mg/ml).
Trial: NCT01933958
Drug: Regorafenib (Stivarga, BAY73-4506)
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The usual dosage is 160 mg of Regorafenib/ STIVARGA taken orally after meal once daily for 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks.
Trial: NCT03630211
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stem Cell Mobilization
Trial: NCT03630211
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Transplantation Conditioning
Trial: NCT03630211
Drug: Alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transplantation Conditioning
Trial: NCT03630211
Drug: Thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Transplantation Conditioning
Trial: NCT03630211
Drug: GM-CSF
RxNorm normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transplantation Conditioning
Trial: NCT03630211
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transplantation Conditioning
Trial: NCT03630211
Drug: Anti Thymocyte Globulin
RxNorm normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transplantation Conditioning
Trial: NCT03098836
Drug: Abiraterone Acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1000 mg orally daily
Trial: NCT03098836
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg orally twice daily (for total daily dose 10 mg)
Trial: NCT00109200
Drug: Xolair (omalizumab)
RxNorm normalized name: omalizumab Injection [Xolair]
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00002665
Drug: asparaginase
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10,000 units/d IV or IM 15 - 24
Trial: NCT00002665
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cons: 75 mg/m2/d IV Push 2 - 5, 9 - 12, 6 - 19, 23 - 26
Trial: NCT00002665
Drug: daunorubicin hydrochloride
RxNorm normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ind: 60 mg/m2 IV 22 and 23
Trial: NCT02976012
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: . Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) \<21 days prior to vitrectomy and one intraoperative intravitreal aflibercept at end of surgery. Eyes will be randomized on the day of surgery or 1-2 weeks post-operatively to either a q8week IAI dosing regimen group or a q16week IAI dosing regimen group.
Trial: NCT00530400
Drug: cefuroxime
RxNorm normalized name: Cefuroxime
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: preoperative intravenous 1.5g cefuroxime
Trial: NCT00002665
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: main: 10 mg/m2/day PO 1 - 28
Trial: NCT00002665
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg based on ideal body weight day -3
Trial: NCT00002665
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ind: 60 mg/m2/d PO 1 - 21\*, 22 - 28 Patients will receive full dose through day 8 and then tapered to zero between Day 29 and 42.~ind2: 60 mg/m2/d PO through day 42
Trial: NCT00002665
Drug: thioguanine
RxNorm normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: main: 60 mg/m2/day PO 1 - 14
Trial: NCT00002665
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ind: 1.4 mg/m2 2 mg max, IV 1, 8, 15, and 22 ind2: 1.4 mg/m2 2 mg max IV 29 and 36 main: 1.5 mg/m2 2 mg max, IV 1, 8, 15, and 22
Trial: NCT03439436
Drug: xylo+dex nasal spray (0.1 mg+5 mg/dose)
RxNorm normalized name: Dex
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
Trial: NCT00257725
Drug: B-MPH
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage form is a 20 mg capsule to be given once daily in the morning for 30 days
Trial: NCT01858532
Drug: Atrasentan
RxNorm normalized name: ATRASENTAN
DrugBank: Atrasentan (DB06199)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT00922480
Drug: Fimasartan
RxNorm normalized name: Fimasartan
DrugBank: Fimasartan (DB09279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan 60 \~ 120mg/po take one tablets once a day
Trial: NCT00922480
Drug: Losartan (Control)
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg \~ 100 mg/po, take one tablets once a day
Trial: NCT01994382
Drug: Cerdulatinib
RxNorm normalized name: Cerdulatinib
DrugBank: Cerdulatinib (DB15499)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT04558580
Drug: Rufinamide
RxNorm normalized name: Rufinamide
DrugBank: Rufinamide (DB06201)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rufinamide
Trial: NCT01015144
Drug: Tulip
RxNorm normalized name: TULIPA KAUFMANNIANA BULB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients were divided into two groups: A, who were administered atorvastatin 40 mg daily for two months and 10 mg for next 4 months; and group B, 4 who were treated according to current guidelines without statin therapy.
Trial: NCT00864890
Drug: Citalopram HBr 40 mg tablets, single dose
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A: Experimental Subjects received Purepac formulated products under fed conditions
Trial: NCT04186936
Drug: Combination Caplet with Loperamide HCl and Simethicone
RxNorm normalized name: loperamide hydrochloride / simethicone Pill
DrugBank: Loperamide (DB00836)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive combination caplet with loperamide HCl 2 mg and simethicone 125 mg as Test product A per assigned treatment sequence.
Trial: NCT04186936
Drug: Loperamide HCl
RxNorm normalized name: loperamide HCl
DrugBank: Loperamide (DB00836)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive loperamide HCl 2 mg tablet-lyophilizate orally as part of Reference product B per assigned treatment sequence.
Trial: NCT04186936
Drug: Simethicone
RxNorm normalized name: Simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Simethicone 40 mg capsule orally as part of Reference product B per assigned treatment sequence.
Trial: NCT03343067
Drug: elagolix
RxNorm normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT01285453
Drug: vadimezan
RxNorm normalized name: Vadimezan
DrugBank: Vadimezan (DB06235)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01129674
Drug: LY2140023
RxNorm normalized name: LY2140023
DrugBank: LY2140023 (DB05096)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, twice daily for 104 weeks
Trial: NCT01129674
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
Trial: NCT01129674
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
Trial: NCT01129674
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
Trial: NCT01129674
Drug: Quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
Trial: NCT00428129
Drug: microplasmin
RxNorm normalized name: Microplasmin
DrugBank: Ocriplasmin (DB08888)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 20mg with Trellis-8 15cm Treatment length 40mg with Trellis-8 30cm Treatment length
Trial: NCT01225887
Drug: Nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT02869438
Drug: Benralizumab
RxNorm normalized name: Benralizumab
DrugBank: Benralizumab (DB12023)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Benralizumab administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)
Trial: NCT02361944
Drug: Oxygen - normoxia
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Trial: NCT02361944
Drug: Oxygen - hyperoxia
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Trial: NCT00120861
Drug: valopicitabine
RxNorm normalized name: Valtorcitabine
DrugBank: Valopicitabine (DB13920)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00120861
Drug: pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00120861
Drug: ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes